secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2025-10-20T23:59:59+00:00
Accession:  0001193125-25-242917
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent reports Phase 2 FID-007 combo data: 51% ORR, PFS 7.8 months in R/M HNSCC
--------------------------------------------------------------------------------

- Preliminary Phase 2 data for FID-007 + cetuximab in 1L-2L R/M HNSCC; 39 patients randomized.
- Overall ORR 51% (75 mg/m2: 44%, 125 mg/m2: 59%); median PFS 7.8 months vs historical 2.3 months.
- Treatment-related SAE rate 6%; no grade 3+ peripheral neuropathy; common grade 3+ events include lymphopenia (19%) and neutropenia (17%).
- Data presented at ESMO 2025 on October 20; optimal dose to be determined after data maturation.
- CEO Ming Hsieh cites steady advancement of FID-007 and strong momentum in precision diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525242917/0001193125-25-242917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312525242917/flgt-20251020.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-242917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer